Genetics and Heart Health After Cancer Therapy

Inclusion Criteria

- ≥18 years of age

- Initial diagnosis of Breast Cancer in 2005 or later

- Documented BRCA testing (results from a local laboratory are acceptable) showing

- confirmation of a germline mutation in BRCA1 or BRCA2 that is predicted or
suspected to be deleterious OR

- confirmation that no mutation was detected in BRCA1 or BRCA2

- Non-carriers will have been treated with an anthracycline-based chemotherapy regimen;
carriers may or may not have been treated with an anthracycline-based chemotherapy
regimen.

- Approximately at least 12 months from initiation of adjuvant treatment or neo-adjuvant
chemotherapy

- Able to provide informed consent

Exclusion Criteria

- Stage IV Breast Cancer

- Genetic testing confirming a variant of unknown significance (VUS) or benign
polymorphism in BRCA1 or BRCA2

- V02 Testing contraindicated for any reason, including:

- Myocardial infarction (within past 3 months)

- High-risk unstable angina;

- High-risk or uncontrolled cardiac arrhythmias;

- Symptomatic severe aortic stenosis;

- Uncontrolled symptomatic heart failure;

- Acute pulmonary embolus or pulmonary infarction;

- Acute myocarditis or pericarditis;

- Acute aortic dissection;

- Coronary revascularization procedure within the past three months;

- Uncontrolled hypertension, defined as systolic blood pressure ≥ 180mmHg or
diastolic blood pressure ≥ 100mmHg;

- Clinically significant valvular heart disease (severe stenosis or regurgitation);

- Known aortic aneurysm; or

- Any other condition which, in the opinion of the investigator, may impede testing
of the study hypothesis or make it unsafe to engage in the V02 test

- Women who are pregnant

- Any other clinically significant medical disease or condition that, in the
investigator's opinion, may interfere with protocol adherence or a subject's ability
to give informed consent